Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 1/2009

01-01-2009 | Adis Drug Profile

Eslicarbazepine Acetate

Authors: Paul L. McCormack, Dean M. Robinson

Published in: CNS Drugs | Issue 1/2009

Login to get access

Abstract

▴ Eslicarbazepine acetate, a prodrug of eslicarbazepine (S-licarbazepine), is a novel, voltage-gated sodium channel antagonist under development for the adjunctive treatment of adult patients experiencing treatment-refractory partial-onset seizures.
▴ In phase III trials, eslicarbazepine acetate 800 and 1200 mg once daily significantly reduced seizure frequency compared with placebo over 12 weeks of maintenance treatment in adults experiencing partial-onset seizures who were taking 1–3 concomitant antiepileptic drugs.
▴ During long-term, open-label treatment for up to 1 year, eslicarbazepine acetate at a median dosage of 800 mg once daily produced sustained reductions from baseline in seizure frequency.
▴ Long-term treatment with eslicarbazepine acetate significantly improved from baseline health-related quality of life as assessed by the Quality-of-Life in Epilepsy Inventory-31 instrument. Similarly, eslicarbazepine acetate significantly reduced depressive symptoms assessed by the Montgomery-Asberg Depression Rating Scale.
▴ Eslicarbazepine acetate was generally well tolerated in clinical trials. The majority of treatment-emergent adverse events were of mild to moderate severity and most occurred early in treatment.
Literature
1.
2.
Brodie MJ. Management strategies for refractory localizationrelated seizures. Epilepsia 2001 Jul; 42Suppl. 3: 27–30CrossRef
3.
Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 2007 Jan; 4(1): 88–96CrossRef
4.
Benes J, Parada A, Figueiredo AA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-digydro-5H-dibenz [b,f]azepine-5-carboxamide derivatives. J Med Chem 1999 Jul 15; 42(14): 2582–7CrossRef
5.
Bonifacio MJ, Sheridan RD, Parada A, et al. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 2001 May; 42: 600–8CrossRef
6.
Sierra-Paredes G, Oreiro-Garcia MT, Vazquez-Illanes MD, et al. Effect of eslicarbazepine acetate (BIA 2-093) on latrunculin A-induced seizures and extracellular amino acid concentrations in the rat hippocampus. Epilepsy Res 2007 Oct; 77(1): 36–43CrossRef
7.
Ambrosio AF, Silva AP, Malva JO, et al. Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochem Pharmacol 2001 May 15; 61: 1271–5CrossRef
8.
Ambrosio AF, Silva AP, Araujo I, et al. Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024. Eur J Pharmacol 2000 Oct 13; 406: 191–201CrossRef
9.
Potschka H, Pekcec A, Soares-Da-Silva P. Inhibition of kindling progression by eslicarbazepine acetate and licarbazepine [abstract no. p071]. Epilepsia 2007 Oct; 48Suppl. 7: 58–9
10.
Sierra-Paredes G, Nunez-Rodriguez A, Vazquez-Lopez A, et al. Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats. Epilepsy Res 2006 Dec; 72(2–3): 140–6CrossRef
11.
Almeida L, Nunes T, Gutierrez MJ, et al. A randomized, doubleblind, placebo- and moxifloxacin-controlled, 4 period crossover trial to evaluate the effects of eslicarbazepine acetate on cardiac repolarization in healthy subjects [abstract plus poster]. 8th European Congress on Epileptology; 2008 Sep 21–25; Berlin
12.
Almeida L, Soares-da-Silva P. Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J Clin Pharmacol 2004 Aug; 44(8): 906–18CrossRef
13.
Almeida L, Falcao A, Maia J, et al. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 2005 Sep; 45(9): 1062–6CrossRef
14.
Falcao A, Maia J, Almeida L, et al. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharm Drug Dispos 2007 Jul; 28(5): 249–56CrossRef
15.
Maia J, Vaz-da-Silva M, Almeida L, et al. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs R D 2005; 6(4): 201–6CrossRef
16.
Nunes T, Maia J, Almeida L, et al. Pharmacokinetic interaction between eslicarbazepine acetate and lamotrigine in healthy subjects [abstract no. 3.248]. Epilepsia 2007 Oct; 48Suppl. 6: 339–40
17.
Almeida L, Falcao A, Maia J, et al. Steady-state pharmacokinetics of once-daily and twice-daily regimens of eslicarbazepine acetate (BIA 2-093) in healthy subjects [abstract no. 2.102]. Epilepsia 2006 Oct; 47Suppl. 4: 154
18.
Maia J, Almeida L, Vaz-da-Silva M, et al. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics of digoxin in healthy subjects [abstract no. 2.261]. Epilepsia 2005 Oct 1; 46Suppl. 8: 178–9
19.
Perucca E, Falcão A, Maia J, et al. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with epilepsy [abstract plus poster]. 8th European Congress on Epileptology; 2008 Sep 21–25; Berlin
20.
Maia J, Almeida L, Falcao A, et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther 2008 Mar; 46(3): 119–30CrossRef
21.
Almeida L, Potgieter JH, Maia J, et al. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 2008 Mar; 64(3): 267–73CrossRef
22.
Elger C, Halász P, Maia J, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-301 study [abstract plus poster]. 8th European Congress on Epileptology; 2008 Sep 21–25; Berlin
23.
Elger C, Bialer M, Cramer JA, et al. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007 Mar; 48(3): 497–504CrossRef
24.
Hufnagel A, Ben-Menachem E, Gabbai AA, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 study [abstract plus poster]. 8th European Congress on Epileptology; 2008 Sep 21–25; Berlin
25.
Lopes-Lima J, Gil-Nagel A, Maia J, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-303 study [abstract plus poster]. 8th European Congress on Epileptology; 2008 Sep 21–25; Berlin
26.
Guekht A, Elger C, Halász P, et al. Long-term treatment of partial epilepsy with eslicarbazepine acetate: results of a 1-year open-label extension study [abstract plus poster]. 8th European Congress on Epileptology; 2008 Sep 21–25; Berlin
27.
Cramer J, Maia J, Almeida L, et al. Quality-of-life improvement during long-term treatment with eslicarbazepine acetate [abstract plus poster]. 8th European Congress on Epileptology; 2008 Sep 21–25; Berlin
28.
Hodoba D, Czlonkowska A, Cramer J, et al. Depressive symptoms improvement during long-term treatment with eslicarbazepine acetate [abstract plus poster]. 8th European Congress on Epileptology; 2008 Sep 21–25; Berlin
29.
Fontes-Ribeiro C, Macedo T, Nunes T, et al. Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, open-label, crossover, single-centre study in healthy volunteers. Drugs R D 2008; 9(6): 447–54CrossRef
Metadata
Title
Eslicarbazepine Acetate
Authors
Paul L. McCormack
Dean M. Robinson
Publication date
01-01-2009
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 1/2009
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/0023210-200923010-00005

Other articles of this Issue 1/2009

CNS Drugs 1/2009 Go to the issue

Therapy in Practice

Psychopharmacological Treatment of Oppositional Defiant Disorder

Review Article

Getting into the Brain

Adis Drug Profile

Ropinirole Prolonged Release

Original Research Article

Effectiveness of Lithium in Children and Adolescents with Conduct Disorder

Review Article

Withdrawing Benzodiazepines in Primary Care